SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-19-030064
Filing Date
2019-08-07
Accepted
2019-08-07 16:10:38
Documents
14
Period of Report
2019-08-07
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ctmx-8k_20190807.htm   iXBRL 8-K 37097
2 EX-99.1 ctmx-ex991_158.htm EX-99.1 303187
3 GRAPHIC g1eawp1cdlcx000001.jpg GRAPHIC 11059
  Complete submission text file 0001564590-19-030064.txt   499069

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ctmx-20190807.xsd EX-101.SCH 5949
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE ctmx-20190807_lab.xml EX-101.LAB 18737
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ctmx-20190807_pre.xml EX-101.PRE 11160
7 EXTRACTED XBRL INSTANCE DOCUMENT ctmx-8k_20190807_htm.xml XML 3441
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37587 | Film No.: 191005554
SIC: 2834 Pharmaceutical Preparations